News

Stabilizing mRNA LNPs via controlled, continuous freeze-drying

Lyophilization is considered to be one of the most promising approaches to stabilize mRNA-LNP formulations and enhance their stability at refrigerated or even room temperatures.

However, lyophilization is a slow, expensive, poorly controlled, and labor-intensive process. Consequently, these disadvantages hamper the fast and cost-efficient development of mRNA-LNP vaccines.

Download the White Paper describing the advantages associated with a RheaVita’s NextGen continuous and controlled lyophilization. This drying technology allows the R&D team and the MSAT team to save money and staffing. It opens a path for seamless scaling-out without the need to reformulate lyophilization protocols. All this may result in a faster time to the market for your mRNA drug or vaccine.

Download by clicking the thumbnail below.

For the most up to date news, please follow us on LinkedIn via the link below

LinkedIn